BiOasis Technologies Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Employees
  • 6
Employees
  • Stock Symbol
  • BTI
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.22
  • (As of Friday Closing)

BiOasis Technologies General Information

Description

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier. Its source of revenue involves the research and license revenue.

Contact Information

Website
www.bioasis.us
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Stock Exchange
TSX
Primary Office
  • 14 Water Street
  • Guilford, CT 06437
  • United States
+1 (203) 000-0000

BiOasis Technologies Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BiOasis Technologies Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.22 $0.23 $0.19 - $0.55 $16.3M 72.1M 36.4K -$0.02

BiOasis Technologies Financials Summary

In Thousands,
USD
TTM 31-Aug-2021 FY 2021 28-Feb-2021 FY 2020 29-Feb-2020 FY 2019 28-Feb-2019
EV 12,839 18,530 10,847 17,795
Revenue 0 3,055 457 1,086
EBITDA (868) 595 (2,971) (2,600)
Net Income (1,035) 523 (3,059) (2,654)
Total Assets 3,205 2,571 703 1,326
Total Debt 1,409 89 749 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BiOasis Technologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BiOasis Technologies‘s full profile, request access.

Request a free trial

BiOasis Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development
Drug Delivery
Guilford, CT
6 As of 2021
00.000
000000000 00.000

00000000

t, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. U
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000

00000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000 000000000
Gaithersburg, MD
00 As of 0000
00000
000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BiOasis Technologies Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Surrozen Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
0000000000 Venture Capital-Backed Gaithersburg, MD 00 00000 000
0000000 0000000000 Formerly VC-backed Waltham, MA 00 00000 000000000 00000
0000000 Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 23 competitors. Get the full list »

BiOasis Technologies Patents

BiOasis Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3813867-A1 Treatment of lymmphatic metastases Pending 22-Jul-2018 000000000
CA-3107332-A1 Treatment of lymphatic metastases Pending 22-Jul-2018 000000000
CA-3094179-A1 Bifunctional blood brain therapies Pending 22-Mar-2018 000000000
JP-2021518392-A Bifunctional blood-brain treatment Pending 22-Mar-2018 00000000000
AU-2019240218-A1 Bifunctional blood brain therapies Pending 22-Mar-2018 C07K14/79

BiOasis Technologies Executive Team (13)

Name Title Board Seat Contact Info
Deborah Rathjen Ph.D Chief Executive Officer & Chairman
Christine Antalik Chief Financial Officer
Dave Jenkins Chief Financial Officer
Mei Tian Ph.D Executive & Vice President
You’re viewing 4 of 13 executive team members. Get the full list »

BiOasis Technologies Board Members (8)

Name Representing Role Since
00000 000000 Self Board Member 000 0000
0000000 0000000 00.0 BiOasis Technologies Chief Executive Officer & Chairman 000 0000
0000 000000 BiOasis Technologies Board Member 000 0000
0000 000000 Self Board Member 000 0000
00000 0000000000 00.0 BiOasis Technologies Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

BiOasis Technologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BiOasis Technologies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BiOasis Technologies‘s full profile, request access.

Request a free trial

BiOasis Technologies Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0.0. 00000000 27-Mar-2008 0000000000 Holding Companies 0000000 0
To view BiOasis Technologies’s complete acquisitions history, request access »